B-prolymphocytic leukemia (B-PLL) is a rare disease with poor prognosis. To further characterize the biological features of this disease, we analyzed immunoglobulin heavy chain (IgVH) mutations, ZAP-70 and CD38 in 19 cases with de novo B-PLL. Immunoglobulin heavy chain genes analysis showed an unmutated pattern (498% homology to germ line) in 9/17 cases (53%), with 100% homology in eight. In the remaining, it ranged from 90 to 97.4%, with three cases slightly mutated (98-95%) and five heavily mutated (o95%). All B-PLL utilized members of VH3 (11/17) and VH4 (6/17) families, with V3-23, V4-59 and V4-34 gene accounting for more than half of them, regardless of mutational status. ZAP-70, assessed by flow cytometry, ranged from 1 to 91% cells, being X20% in 57% of cases. CD38 ranged from 1 to 99% (median 21%). There was no correlation between IgVH status and ZAP-70 or CD38 expression, but male gender and del(17p) were more common in the unmutated group. Neither IgVH mutations, CD38 expression nor del(17p) influenced patients' outcome. Unexpectedly, ZAP-70 þ B-PLL patients survived longer (40 months) than ZAP-70À B-PLL (8 months). B-PLL appears biologically heterogeneous regarding IgVH mutations, ZAP-70 and CD38 expression, showing a pattern distinct from that of other lymphoproliferative disorders.
Introduction
B-cell prolymphocytic leukemia (B-PLL) is a rare disease, accounting for 1% of the chronic lymphoid leukemias. First described in the early seventies, 1,2 B-PLL is now recognized as a specific entity in the WHO classification. 3 The disease is characterized by massive splenomegaly, absence of lymphadenopathy, marked lymphocytosis (usually4100 Â 10 9 /l), anemia and thrombocytopenia.
The hallmark of the disease is the presence of circulating prolymphocytes exceeding 55% of the lymphoid cells; cases of 'transformed' chronic lymphocytic leukemia (CLL) or CLL with increased prolymphocytes (CLL/PL) (410% and o55%) have different biological and genetic features and should not be considered as B-PLL. 3 Although there is no specific cytogenetic marker, chromosomal abnormalities in B-PLL include a high incidence of p53 gene deletions/mutations, which underline its aggressive course. 4 Deletions at 11q23 and 13q14 have also been described, 5 while trisomy 12 is rare. B-cell prolymphocytic leukemia with t(11;14) have been documented (up to 20% of cases), but the majority if not all of them represent a leukemic form of mantle cell lymphoma (MCL). 6 The disease course is aggressive and prognosis remains unsatisfactory, with poor response to chemotherapy and short survival.
There is no information in B-PLL regarding the expression of CD38 and ZAP-70, two prognostic markers described in CLL. Only one study 7 on the mutational status of the variable region of immunoglobulin heavy chain genes (IgVH) in 11 cases of B-PLL suggested the prevalence of a mutated pattern, consistent with the origin from a postgerminal center B cell. We have performed IgVH gene analysis on a further 19 well defined B-PLL cases and correlated IgVH gene mutational status with expression of CD38 and ZAP-70, cytogenetic abnormalities and clinical outcome.
Materials and methods

Nineteen patients with B-PLL diagnosed between February 1985
and April 2004, were selected for this study. There were nine female and 10 male patients with a median age at diagnosis of 71 years (range 42-91 years). All but two were untreated at the time of the study. Among 14 cases with available clinical information, the median WBC count was 145 Â 10 9 /l (range 35-429), Hb 9.5 g/dl (range 6.1-12.2) and platelet count 118 Â 10 9 /l (range 49-294); all had splenomegaly and only one had lymphadenopathy. Diagnosis was based on clinical features, peripheral blood morphology reviewed by two of us (EM and DC) and immunophenotype (CLL scores p3). Immunophenotypic features are detailed in Table 1 . Chronic lymphocytic leukemia score was 0 in 12 cases, 1 in two cases, 2 in one case, 3 in two cases and was not available in two cases (both CD5À). Four cases were CD5 þ , and two of them were also CD23 þ ; the intensity of CD5 expression was weak to moderate, CD79b and sIg intensity was mostly strong. Bone marrow (three) and/or spleen (four) histology was available in five cases. Diagnosis of MCL was excluded by the absence of t (11;14) in all 17 cases in which fluorescent in situ hybridization (FISH) was performed, including the four CD5 þ cases. Five patients were treated at our Institution and 14 cases were referred for diagnostic tests from other hospitals. Treatment details of 14 patients with available clinical information are provided in Table 2 . Six patients with del(p53) evaluable for response received a total of 14 lines of chemotherapy, achieving a response in half of the cases (in two out of six alkylating agents based regimens, four out of six purine analogs regimens, one out of two cases treated with Campath). Four patients without del(p53) evaluable for response received a total of eight lines of therapy, achieving a response in 87.5% of the cases (in three out of four alkylating agents based regimens and all the four lines of purine analogs). Difference in percentage of responses among the two groups was not significant (Po0.1). Although numbers are too small to draw further conclusions, it is worth noting that long lasting complete responses were achieved in two patients, after treatment with splenectomy plus Campath (patient #2) and fludarabine (patient #7), respectively. Patient #17 survived with stable disease 3 years after splenectomy without any further treatment.
Immunoglobulin heavy chain study
Immunoglobulin variable region genes were sequenced in 18 cases on thawed cells from dimethylsulphoxide (DMSO) frozen vials as described. 8 Briefly, complementary DNA (cDNA) was synthesized by reverse transcription using an oligo (dT) primer (Promega, Madison, WI, USA) from RNA extracted from peripheral blood lymphocytes that had been stored in DMSO at À701C. cDNA was amplified by polymerase chain reaction (PCR) using a mixture of oligonucleotide 5 0 primers specific for each leader sequence of the V H 1 to V H 6 families or consensus 5 0 FR1 primer, together with either a consensus 3 0 primer complementary to the germline J H regions or a 3 0 primer complementary to the constant region. Clonal sequences were 
Flow cytometry analysis of ZAP-70 and CD38
ZAP-70 expression was tested in 18 cases (17 peripheral blood; one bone marrow) by 4-color flow cytometry, as previously described 9,10 using an unconjugated monoclonal antibody (clone 2F3.2, Upstate Biotechnology, Waltham, MA, USA) on fresh mononuclear cells (four cases) or previously frozen cells thawed from DMSO vials (14 cases). A marker including the T/NK cells (CD3 þ /CD56 þ cells, positive control) was used to define the percentage of B-PLL cells (CD5À/CD19 þ or CD5 þ / CD19 þ ) that expressed ZAP-70 with the same intensity of fluorescence as the T/NK cells. The cutoff point for ZAP-70 positivity was X20% of leukemic cells. To ensure that results were reliable in frozen samples, ZAP-70 was tested on both fresh and frozen cells in two cases (one ZAP-70 þ and one ZAP-70À) and findings were consistent.
Flow cytometry of CD38 was performed in 13 cases on fresh whole-blood samples (12) or frozen cells (1) stained with CD5-FITC (BD Biosciences, San Josè, CA, USA), CD38-PE (clone HB-7, BD Biosciences) and CD19-TC (Caltag, Burlingame, CA, USA), as previously described. 11 Two cutoff points (X30 and X7%) for CD38 positivity were used.
Fluorescent in situ hybridization analysis
Fluorescent in situ hybridization analysis was performed in 17 cases with directly labeled commercial probes (Vysis, Downers Grove, IL, USA/Abbott diagnostics, South Pasadena, CA, USA) to detect del13q14 (D13S25), del17p13 (p53 locus) and trisomy 12 (D12Z3), according to manufacturers protocols subsequent to 70% formamide denaturation of the slides. Cutoff values for each probe were established on peripheral blood mononuclear cells from healthy normal controls and were 5% for 13q and 17p, 2% for trisomy 12.
Statistical analysis
Overall survival (OS) was calculated from date of diagnosis to date of last follow-up or death. Life table curves were calculated using the Kaplan-Meier method and compared with the logrank test. Fisher's exact test was used to compare the distribution of biological features between mutated and unmutated B-PLL. Po0.05 was required for significance.
Results
Mutational analysis and VH usage in B-cell prolymphocytic leukemia
Eighteen different productive IgVH gene sequences were identified from the 17 evaluable patients. Of cases, 53% (9/17) had a sequence homology of 498% with their closest germline counterpart (unmutated), and in eight of these nine cases the homology was 100%. The homology of those with a mutated pattern (o98% homology to germ line) ranged from 90 to 97.4% (mean 94.5%), with three cases slightly mutated (from 98 to 95%) and five heavily mutated (o95%). All cases utilized members of the VH3 (11/17) and VH4 (6/17) families, with V3-23 constituting 45% (5/11) of VH3s, and V4-59 (2/6) and V4-34 (2/6) 66% of the VH4 cases (Figure 1 ). Both mutational subsets were observed in genes from the VH3 and VH4 families. DH gene segments from families 3, 4, 5 and 6 and JH genes from all six families were utilized by the 17 cases.
ZAP-70, CD38 and fluorescent in situ hybridization
ZAP-70 expression in B-prolymphocytes ranged from 1 to 91% (median 28%) and eight out of 14 (57%) evaluable cases were considered ZAP-70 þ (X20%).
CD38 expression ranged from 1 to 99% (median 21%). In six out of 13 (46%) cases CD38 was expressed in X30% of cells, (Table 3) showed del(17p) in 9/17 (53%) cases; in each case the deletion was present in more than 80% of the cells. Del(13q) was detected in 3/11 (27%) cases; in two cases it was hemizygous. All three del(13q) cases also showed del(17p). Trisomy 12 was not detected in the nine cases tested for this abnormality. Table 3 summarizes the results of IgVH mutations, ZAP-70/CD38 expression and chromosome abnormalities as detected by FISH.
Correlation between immunoglobulin heavy chain, ZAP-70, CD38, chromosomal abnormalities and clinical outcome
Correlation between IgVH status and other features is shown in Tables 4, 5 and 6. A different gender distribution was present among the unmutated and mutated B-PLL, with a male/female ratio of 2 and 0.6, respectively. No difference was observed in the age at diagnosis.
There was no correlation between ZAP-70 expression and IgVH mutations. Thus, ZAP-70 was expressed in 57% of unmutated B-PLL and in 67% of mutated cases (P ¼ 0.4). Neither was a correlation found between CD38 expression and IgVH mutations. CD38 (X30%) was positive in 20% of unmutated B-PLL and in 71% of the mutated ones (P ¼ 0.1). Using a cutoff at X7%, CD38 was shown to be positive in 40% of unmutated B-PLL and in all the mutated (P ¼ 0.4).
Among the unmutated group, there was an increased prevalence of del(17p) (75%) and del(13q) (50%) (pX0.1), although statistically not significant.
The median overall survival (OS) was 35 months. Three patients (all mutated) are alive at 86 months (range 51-132 months) from diagnosis, 15 (of which nine unmutated and four mutated) died at 17 months (range 1-84 months) and one was lost to follow-up at 4 months (Tables 5 and 6 ).
Patients with unmutated or mutated IgVH had a median OS of 21 and 40 months, respectively, but the difference was not statistically significant (P ¼ 0.24). Similarly, patients with or without del(17p) had a median OS of 12 and 40 months, respectively (P ¼ 0.24). There were no statistical differences in OS between CD38 þ and CD38À cases (P ¼ 0.67, considering both cutoff points) as well as ZAP-70 þ and ZAP-70À cases (P ¼ 0.1); however, unexpectedly, we observed a trend towards a longer OS in ZAP-70 þ cases (40 months) than ZAP-70À (8 months).
Discussion
Immunoglobulin heavy chain mutational status and ZAP-70/ CD38 expression represent three new biological characteristics of B-cell disorders, with a well-recognized prognostic value in CLL. This study analyzed a series of B-PLL with regard to these parameters, aiming to provide new insights on the biology of this rare leukemia. Only cases with stringent diagnostic criteria (detailed review of lymphocyte morphology and exclusion of t (11;14) by FISH) were included.
We have shown that B-PLL appears heterogeneous regarding IgVH mutational status, with 47% mutated and 53% unmutated cases and a wide range of mutation rate. Only one previous study 7 analyzed the IgVH genes in 11 cases of B-PLL, and in contrast to our results described the presence of mutations in all, consistent with a postgerminal center B-cell origin. In another study Wagner et al. 12 documented no somatic mutations in the variable region of the light chain genes (IgVk) in six B-PLL cases. It is unclear why results from these two reports and ours appear to be discordant. Possible explanations are the limited number of cases in each series and different criteria in patients' population selection (i.e. we excluded the presence of t (11;14) and CLL/PL morphology in our cases). Nevertheless, we confirmed the predominant usage of the VH3 and VH4 family, 
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IgVH, ZAP-70 and CD38 in B-PLL I Del Giudice et al particularly the V3-23, V4-34 and V4-59 genes, previously described by Davi et al. 7 ( Figure 1 ). Heterogeneity in IgVH mutational status is a well-known feature of CLL and MCL, a neoplasm that in its leukemic form has similarities with CLL and B-PLL. Analysis of the IgVH variable, diversity and joining genes in large series of patients with CLL has shown biased IgVH gene usage, restricted CDR3 homology in 10À15% of cases, consistent with antigen selection, and a worse prognosis for the 50% of cases with unmutated IgVH genes. 8, 13 In CLL, there is also a strong correlation between unmutated IgVH genes, expression of ZAP 70, CD38, and poor risk cytogenetic abnormalities such as del(17p) and del(11q). 9, 10, [14] [15] [16] [17] Immunoglobulin gene sequencing in smaller series of patients with either MCL [18] [19] [20] [21] or splenic marginal zone lymphoma (SMZL) 22 also shows biased IgVH gene usage and either mutated or unmutated IgVH genes (Table 7) . However, in contrast to CLL there is no clear association between IgVH gene mutational status, ZAP-70 and CD38 expression or cytogenetic abnormalities in these two disorders [18] [19] [20] [21] [22] . Interestingly, in B-PLL we found no VH1 family gene expression and no V3-21 or V3-30 genes, which are well represented in CLL, 23, and SMZL 22 (Table 7) . Also, in B-PLL there was no difference in the IgVH mutational status with respect to the use of specific VH genes and no preferential usage of any particular family of DH and JH genes, in contrast to CLL and MCL.
In order to see whether the biological features of CLL/PL were more similar to B-PLL, we compared our B-PLL cases to a series of 56 CLL/PL. There was a different pattern of VH genes usage (Table 7) between them, further suggesting that B-PLL is a specific entity rather than just an aggressive form of CLL. However, this interpretation of the results should be taken with caution owing to the limited number of B-PLL examined.
ZAP-70 and CD38 expression have not been previously described in B-PLL. Our findings demonstrate that B-PLL expresses ZAP-70 and CD38 in greater than half of the cases, appearing heterogeneous as in CLL and MCL. In CLL, ZAP-70 has been shown to be expressed from one third to 50% of cases, and proposed as a poor prognostic marker; 9,10,14-17 CD38 expression seems to predict short time to progression 10, 11 and worse OS. [25] [26] [27] Among CLL/PL, the frequency of ZAP-70 and CD38 þ cases is higher, being in our series 70 and 94%, respectively (data not shown). In MCL, ZAP-70 tends to be negative 18, 28 and CD38 is expressed in more than half of the cases, although their prognostic value is not clear. 19, 20, 29, 30 In SMZL, CD38 is expressed in about half of the cases 22, 31 and in a recent report it appears to correlate with unmutated IgVH and aggressive clinical behavior. 31 Our series is too small to firmly demonstrate if these markers have a prognostic impact. B-cell prolymphocytic leukemia with unmutated IgVH tended to show an adverse outcome in comparison with mutated cases, although statistical difference was not reached. However, the only three patients alive at more than 5 years from diagnosis, were mutated and with absence of del(17p). There was no difference in outcome between CD38 þ and CD38À B-PLL (regardless of the cutoff point for positivity) and unexpectedly, ZAP-70 þ B-PLL appeared to survive longer than ZAP-70À B-PLL, in contrast with the findings in CLL. However, a prognostic stratification of B-PLL could be not so relevant, owing to the overall poor outcome of the disease. Kienle et al. 18 Algara et al. 22 Davi et al.
7
(Catovsky, Oscier) Ghia et al. 24 Orchard et al. 19 Camacho et al. 20 Walsh et al. We could not show any correlation between IgVH status, ZAP-70 and CD38 in B-PLL, in contrast to the findings in CLL, although an over-representation of male sex and del(17p) in the B-PLL unmutated group was evident.
In conclusion, B-PLL appears heterogeneous regarding IgVH mutational status, ZAP-70 and CD38 expression and this is in line with the heterogeneity already shown in the immunophenotypic (CD5 þ in one-third of cases) and cytogenetic features (presence of p53 deletion/mutation in more than half of cases) of this disease. The pattern of expression of these new biological features of B-PLL suggests that this disease represent a distinct entity, different from CLL or CLL/PL.
